Contact for general questions:

Ryan Eckert, MS, CSCS

Research Coordinator

Mays Cancer Center

UT Health San Antonio MD Anderson

eckertr@uthscsa.edu

 

© 2018-2019 by The MPN QoL Study Group

Published Work //

The MPN QoL Study Group and its research team members have been publishing work related to the advancement of QoL research in MPNs since the late 1990s. Below is a list of publications (peer-reviewed papers and conference abstracts) in descending order beginning with the most recent. If you would like to read more regarding a particular publication(s), hover over the publication and click on it and you will be directed to a website housing the publication.

2019

Iruku P, Goros M, Gelfond J, Chang J, Padalecki S, Mesa R, Kaklamani VG. Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center. Contemporary clinical trials communications. 2019 Sep 1;15:100421.

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019 Jul 30.

Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, Parasuraman S, Colucci P, Paranagama D, Savona MR, Mesa R. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: an Analysis From the REVEAL Study. Clinical Lymphoma Myeloma and Leukemia. 2019 Jun 13.

Palmer J, Kosiorek HE, Wolschke C, Fauble VD, Butterfield III R, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N. Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis. Biology of Blood and Marrow Transplantation. 2019 Jul 6.

Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, Mesa R, Petersen B, Farnoud N, Najfeld V, Rampal R. Oral Idasanutlin in Patients with Polycythemia Vera. Blood. 2019 Jan 1:blood-2018893545.

Rumi E, McMullin MF, Harrison C, Ellis MH, Barzilai M, Sarid N, Mesa R, Paoli C, Angona A, Sant'Antonio E, Ferretti VV. Facing erythrocytosis: results of an international physician survey. American journal of hematology. 2019 May 31.

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N. Corrigendum to" Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib"[Leukemia Res. 79 (2019) 38-44]. Leukemia research. 2019 Jun;81:105.

Mesa RA, Su Y, Woolfson A, Prchal JT, Turnbull K, Jabbour E, Scherber R, Shields AL, Krohe M, Ojo F, Pompilus F. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health and quality of life outcomes. 2019 Dec;17(1):61.

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leukemia research. 2019 Apr 1;79:38-44.

Huberty, J., Eckert, R.,Larkey, L., Mesa, R. Myeloproliferative neoplasm patients experience of using a consumer-based mobile meditation app to improve fatigue: Informing future directions. JMIR Cancer, 5(2), 2019.

Huberty, J, Eckert, R, Dueck, A, Kosiorek, H, Larkey, L, Gowin, K, Mesa, R. Online yoga in myeloproliferative neoplasm patients: Results of a randomized pilot trial to inform future research. BMC complementary and alternative medicine. 2019 Jun 19(1):121.

Gowin K. Living well with a Myeloproliferative neoplasm: A guide for patients and caregivers. Spry Publishing. 2019. ASIN: B07QLB3MSD

Huberty J, Eckert R, Larkey L, Kurka J, Rodriguez S, Yoo W, Mesa R. Smartphone-based meditation for myeloproliferative neoplasm patients: A feasibility study to inform future trials. JMIR formative research. 2019 3(2).

Menghrajani K, Boonstra PS, Mercer JA, Perkins C, Gowin KL, Weber AA, Mesa R, Gotlib JR, Wang L, Singer JW, Talpaz M. Predictive models for   splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leukemia & lymphoma. 2019 Apr 60(4):1036-1042.

Palmer J, Scherber R, Girardo M, Geyer H, Kosiorek H, Dueck A, Jain T, Mesa R. Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. Biology of Blood and Marrow Transplantation. 2019 Feb 1;25(2):398-402.

Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L. Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biology of Blood and Marrow Transplantation. 2019 Feb 1;25(2):256-64.

Jain T, Kunze KL, Temkit MH, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplantation. 2019 Feb;54(2):204.

Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey. Annals of hematology. 2019 Jan 29:1-7.

Mazza GL, Kunze KL, Langlais BT, Kosiorek HE, DeWees TA, Geyer HL, Scherber RM, Mesa RA, Dueck AC. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies. Leukemia & lymphoma. 2019 Jan 17:1-7.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biology of Blood and Marrow Transplantation. 2019 Jan 6.

2018

Moisa C, Gaman MA, Diaconu CC, Assani AD, Gaman AM. The evaluation of oxidative stress in patients with essential thrombocythemia treated with risk-adapted therapy. Arch Balk Med Union. 2018;53(4):529-534.

Moisa C, Gaman MA, Pascu EG, Assani AD, Dragusin OC, Epingeac ME, Gaman AM. The role of oxidative stress in essential thrombocythemia. Arch Balk Med Union. 2018;53(1):70-75.

Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood advances. 2018 Dec 26;2(24):3572-80.

Eckert R, Huberty J, Dueck A, Kosiorek H, Larkey L, Marks L, Mesa R. The use of meditative movement as a non-pharmacologic symptom management approach in hematological cancer patients: A systematic review of literature. Hematology and medical oncology. 2018 3(4). DOI: 10.15761/HMO.1000168.

 

Vizcaino M, Gowin K, Eckert R, Larkey L, Kosiorek H, Huberty J, Mesa R. Dysregulation in cortisol diurnal activity among myeloproliferative neoplasm cancer patients. Hematology and medical oncology. 2018 3(4).

Mughal TI, Lion T, Abdel‐Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R. Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematological oncology. 2018 Dec;36(5):740-8.

Huberty J, Eckert R, Larkey L, Gowin K, Mitchell J, Mesa R. Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study. Integrative cancer therapies. 2018 Dec;17(4):1150-62.

Yang M, Covington MF, Nguyen BD, Johnson GB, Mesa RA, Roarke MC. 99mTc-Sulfur Colloid Bone Marrow Scintigraphy in Diagnosis of Diffuse Pulmonary Extramedullary Hematopoiesis Secondary to Myelofibrosis. Journal of nuclear medicine technology. 2018 Dec 1;46(4):368-72.

Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, Colucci P, Mesa R. Clinical and disease characteristics from REVEAL at time of enrollment (baseline): prospective observational study of patients with polycythemia vera in the United States. Clinical Lymphoma Myeloma and Leukemia. 2018 Dec 1;18(12):788-95.

Scherber RM, Mesa RA. Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF. ASH Education Program Book. 2018 Nov 30;2018(1):118-26.

Mesa RA. Refining the management of polycythemia vera. Clinical advances in hematology & oncology: H&O. 2018 Sep;16(9):587-9.

Mesa R, Boccia RV, Grunwald MR, Oh ST, Colucci P, Paranagama D, Parasuraman S, Stein BL. Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States. Clinical Lymphoma Myeloma and Leukemia. 2018 Sep 1;18(9):590-6.

Mascarenhas J, Virtgaym E, Stal M, Blacklock H, Gerds AT, Mesa R, Ganly P, Snyder D, Tabbara I, Tremblay D, Moshier E. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Annals of hematology. 2018 Aug 1;97(8):1369-74.

Ma VT, Boonstra PS, Menghrajani K, Perkins C, Gowin KL, Mesa RA, Gotlib JR, Talpaz M. Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clinical Lymphoma Myeloma and Leukemia. 2018 May 1;18(5):e201-10.

Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA oncology. 2018 May 1;4(5):652-9.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 Feb 27:1.

Yu J, Parasuraman S, Paranagama D, Bai A, Naim A, Dubinski D, Mesa R. Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey. BMC cancer. 2018 Dec;18(1):420.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP. Recent advances in the genomics and therapy of BCR/ABL1-positive and-negative chronic myeloproliferative neoplasms. Leukemia research. 2018 Apr 1;67:67-74.

Diaz AE, Mesa RA. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. Future Oncology. 2018 Apr;14(9):797-807.

2017

Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Rare cancers and social media: analysis of twitter metrics in the first 2 years of a rare-disease community for myeloproliferative neoplasms on social media—# MPNSM. Current hematologic malignancy reports. 2017 Dec 1;12(6):598-604.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Te Boekhorst PA, Commandeur S, Schouten H, Sackmann F, Fuentes AK. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia research. 2017 Dec 1;63:34-40.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor–naïve patients with myelofibrosis. Journal of Clinical Oncology. 2017 Sep 20;35(34):3844-50.

Eckert R, Huberty J, Gowin K, Mesa R, Marks L. Physical activity as a nonpharmacological symptom management approach in myeloproliferative neoplasms: recommendations for future research. Integrative cancer therapies. 2017 Dec;16(4):439-50.

Mesa RA. New Guidelines From the NCCN for Polycythemia Vera. Clinical advances in hematology & oncology: H&O. 2017 Nov 1;15(11):848-50.

Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26;130(17):1889-97.

Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. Journal of the National Comprehensive Cancer Network. 2017 Oct 1;15(10):1193-207.

Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Leukemia research. 2017 Oct 1;61:6-9.

Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Ronco JP. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Annals of hematology. 2017 Oct 1;96(10):1653-65.

Geyer H, Mesa RA. Approach to MPN Symptom Assessment. Current hematologic malignancy reports. 2017 Oct 1;12(5):381-8.

Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, Price GL, Giles JL, D’Souza DN, Walgren RA, Prchal JT. A phase 1 study of the Janus kinase 2 (JAK2) V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leukemia research. 2017 Oct 1;61:89-95.

Huberty J, Eckert R, Gowin K, Mitchell J, Dueck AC, Ginos BF, Larkey L, Mesa R. Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms. haematologica. 2017 Oct 1;102(10):e384-8.

Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses. Journal of hematology & oncology. 2017 Dec;10(1):156.

Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leukemia research. 2017 Sep 1;60:11-7.

Jain T, Mesa RA, Palmer JM. Allogeneic stem cell transplantation in myelofibrosis. Biology of Blood and Marrow Transplantation. 2017 Sep 1;23(9):1429-36.

Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S. Practical measures of clinical benefit with ruxolitinib therapy: an exploratory analysis of COMFORT-I. Clinical Lymphoma Myeloma and Leukemia. 2017 Aug 1;17(8):479-87.

Gwaltney C, Paty J, Kwitkowski VE, Mesa RA, Dueck AC, Papadopoulos EJ, Wang L, Feliciano J, Coons SJ. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leukemia research. 2017 Aug 1;59:26-31.

Padrnos L, Mesa RA. Myeloproliferative neoplasms: translating new discoveries into better outcomes, better quality of life. Oncology. 2017 Jul 15;31(7):521-9.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. The Lancet Haematology. 2017 Jul 1;4(7):e317-24.

Palmer J, Mesa R. Transplantation in myelofibrosis reaches the molecular age. Biology of Blood and Marrow Transplantation. 2017 Jul 1;23(7):1043-4.

Ertz-Archambault N, Kosiorek H, Taylor GE, Kelemen K, Dueck A, Castro J, Marino R, Gauthier S, Finn L, Sproat LZ, Palmer J. Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia. JAMA oncology. 2017 Jul 1;3(7):936-43.

Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, Masciulli A, Scarano M, Vannucchi AM, Mesa RA, Barbui T. The potential role of hematocrit control on symptom burden among polycythemia vera patients: insights from the CYTO-PV and MPN-SAF patient cohorts. Leukemia & lymphoma. 2017 Jun 3;58(6):1481-7.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. The Lancet Haematology. 2017 May 1;4(5):e225-36.

Mesa RA. NCCN Debuts New Guidelines for Myeloproliferative Neoplasms. Journal of the National Comprehensive Cancer Network. 2017 May 1;15(5S):720-2.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017 Apr;31(4):896.

Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, Mesa R. Pegylated interferon alpha–2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leukemia research. 2017 Mar 1;54:73-7.

Mesa RA. The new NCCN guidelines for the management of myelofibrosis. Clinical advances in hematology & oncology: H&O. 2017 Mar;15(3):193.

Verstovsek S, Savona MR, Mesa RA, Dong H, Maltzman JD, Sharma S, Silverman J, Oh ST, Gotlib J. A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis. British journal of haematology. 2017 Mar;176(6):939-49.

Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of hematology & oncology. 2017 Dec;10(1):55.

Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of hematology & oncology. 2017 Dec;10(1):55.

Mesa RA. Highlights in myeloproliferative neoplasms from the 2016 American Society of Hematology meeting: Commentary. Clinical advances in hematology & oncology: H&O. 2017 Feb;15(2):21-3.

Verstovsek S, Talpaz M, Ritchie E, Wadleigh M, Odenike O, Jamieson C, Stein B, Uno T, Mesa RA. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 Feb;31(2):393.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. haematologica. 2017 Jan 1;102(1):85-93.

Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017 Jan 1;102(1):94-102.

Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF). British journal of haematology. 2017 Jan;176(1):76-85.

Koren-Michowitz M, Lavi N, Ellis MH, Vannucchi AM, Mesa R, Harrison CN. Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. Annals of hematology. 2017 Jan 1;96(1):87-92.

2016

Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P. Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2016 Dec 1;14(12):1572-611.

Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new Twitter community:# MPNSM. Current hematologic malignancy reports. 2016 Dec 1;11(6):456-61.

Jain T, Mesa R. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. Expert review of anticancer therapy. 2016 Nov 1;16(11):1101-8.

Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. International journal of hematology. 2016 Oct 1;104(4):420-9.

Gowin K, Coakley M, Kosiorek H, Mesa R. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis. haematologica. 2016 Oct 1;101(10):e405-6.

Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, Eriksson N, Mountain JL, Francke U, Tung JY, Nguyen HM, Zhang H. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016 Aug 25;128(8):1121-8.

Singer JW, Al-Fayoumi S, Ma H, Komrokji RS, Mesa R, Verstovsek S. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. Journal of experimental pharmacology. 2016;8:11.

Mesa RA. Recent advances in the management of myelofibrosis. Clinical advances in hematology & oncology: H&O. 2016 Aug 1;14(8):597-9.

Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Zhen H. Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. European journal of haematology. 2016 Aug;97(2):192-200.

Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R, Hehlmann R, Saglio G, Barbui T, Van Etten RA. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2016 Jul 2;57(7):1517-26.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016 Jul 1;101(7):821-9.

Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: an analysis by the MPN QOL International Study Group. Cancer. 2016 Jun 15;122(12):1888-96.

Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016 Jun 1;101(6):660-71.

Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J. Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. Leukemia. 2016 Jun;30(6):1413.

Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC cancer. 2016 Dec;16(1):167.

Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, Geyer HL, McCallister A, Cotter M, Van Husen B, Harrison CN. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016 Feb 1;122(3):477-85.

Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. Journal of Clinical Oncology. 2015 Nov 23;34(2):151-9.

Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, Mesa RA, Virnig BA, Cerhan JR. Hormonal and reproductive factors and risk of myeloproliferative neoplasms in postmenopausal women. Cancer Epidemiology and Prevention Biomarkers. 2016 Jan 1;25(1):151-7.

Mesa RA, Passamonti F. Individualizing care for patients with myeloproliferative neoplasms: integrating genetics, evolving therapies, and patient-specific disease burden. American Society of Clinical Oncology Educational Book. 2016 May;36:e324-35.

2015

Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)—focus on Twitter and the development of a disease-specific community:# MPNSM. Current hematologic malignancy reports. 2015 Dec 1;10(4):413-20.

Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R. Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups. Biology of Blood and Marrow Transplantation. 2015 Nov 1;21(11):1883-7.

Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015 Nov;29(11):2126.

Eremenco S, Oko-Osi H, Arnold B, Savic L, Sterling K, Athearn R, Mesa RA. TRANSLATION AND LINGUISTIC VALIDATION OF THE MODIFIED MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM-TOTAL SYMPTOM SCORE (MMPN-SAF TSS) FOR USE IN 26 COUNTRIES. Value in Health. 2015 Nov 1;18(7):A471-2.

Tibes R, Al-Kali A, Oliver GR, Delman DH, Hansen N, Bhagavatula K, Mohan J, Rakhshan F, Wood T, Foran JM, Mesa RA. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. Journal of hematology & oncology. 2015 Dec;8(1):114.

Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators of inflammation. 2015;2015.

Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. American journal of hematology. 2015 Oct;90(10):864-70.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. haematologica. 2015 Sep 1;100(9):1139-45.

Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A. An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. haematologica. 2015 Sep 1;100(9):1117-30.

Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA oncology. 2015 Aug 1;1(5):643-51.

Geyer HL, Mesa RA. Emerging drugs for the treatment of myelofibrosis. Expert opinion on emerging drugs. 2015 Oct 2;20(4):663-78.

Gowin K, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leukemia research. 2015 Jul 1;39(7):684-8.

Scherber R, Mesa RA. Survival and new cancers with myeloproliferative neoplasms. The Lancet Haematology. 2015 Jul 1;2(7):e272-3.

Mesa RA, Scherber RM, Geyer HL. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leukemia & lymphoma. 2015 Jul 3;56(7):1989-99.

Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia & lymphoma. 2015 Jul 3;56(7):2092-7.

Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2015 Jul 3;56(7):1938-48.

Padrnos L, Dueck AC, Scherber R, Glassley P, Stigge R, Northfelt D, Mikhael J, Aguirre A, Bennett RM, Mesa RA. Quality of life and disease understanding: impact of attending a patient‐centered cancer symposium. Cancer medicine. 2015 Jun;4(6):800-7.

Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Annals of hematology. 2015 Jun 1;94(6):901-10.

Stein BL, O’Brien S, Greenberg P, Mesa RA. The need for United States–based guidelines for myeloproliferative neoplasms. Journal of the National Comprehensive Cancer Network. 2015 May 1;13(5):607-9.

Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, Granston T. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2 (V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23;125(17):2649-55.

Gowin KL, Mesa RA. Profile of pomalidomide and its potential in the treatment of myelofibrosis. Therapeutics and clinical risk management. 2015;11:549.

Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. Journal of the National Comprehensive Cancer Network. 2015 Apr 1;13(4):424-34.

Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clinical Lymphoma Myeloma and Leukemia. 2015 Apr 1;15(4):214-21.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015 Apr 1;100(4):479-88.

Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy. Leukemia & lymphoma. 2015 Oct 3;56(10):2803-11.

Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015 Mar 19;125(12):1857-65.

Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine. 2015 Jan 29;372(5):426-35.

Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clinical Lymphoma Myeloma and Leukemia. 2015 Jan 1;15(1):e1-5.

Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia. 2015 Jan;29(1):20.

Pemmaraju N, Mesa R. Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs). ASH Education Program Book. 2015 Dec 5;2015(1):649-51.

2014

Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how?. Blood. 2014 Dec 4;124(24):3529-37.

Scherber RM, Geyer HL, Mesa RA. Quality of life in MPN comes of age as a therapeutic target. Current hematologic malignancy reports. 2014 Dec 1;9(4):324-30.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ. Use of JAK inhibitors in the management of myelofibrosis: a revision of the B ritish C ommittee for S tandards in H aematology G uidelines for I nvestigation and M anagement of M yelofibrosis 2012. British journal of haematology. 2014 Nov;167(3):418-20.

Mehta J, Wang H, Fryzek JP, Iqbal SU, Mesa R. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leukemia & lymphoma. 2014 Oct 1;55(10):2368-74.

Gowin K, Mesa R. Management of thrombocythemia. F1000Research. 2014;3.

Mascarenhas JO, Cross NC, Mesa RA. The future of JAK inhibition in myelofibrosis and beyond. Blood reviews. 2014 Sep 1;28(5):189-96.

Geyer H, Mesa RA. Assessing disease burden in patients with classic MPNs. Best Practice & Research Clinical Haematology. 2014 Jun 1;27(2):107-19.

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.

Titmarsh GJ, Duncombe AS, McMullin MF, O'rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA. How common are myeloproliferative neoplasms? A systematic review and meta‐analysis. American Journal of Hematology. 2014 Jun;89(6):581-7.

Mascarenhas J, Mesa R, Prchal J, Hoffman R. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. haematologica. 2014 Jun;99(6):945.

Rosenthal A, Mesa RA. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert opinion on pharmacotherapy. 2014 Jun 1;15(9):1265-76.

Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM. Use of the Functional Assessment of Cancer Therapy− Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Clinical therapeutics. 2014 Apr 1;36(4):560-6.

Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the E uropean U nion. European journal of haematology. 2014 Apr;92(4):289-97.

Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, Mesa RA, Virnig BA, Cerhan JR. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. International journal of cancer. 2014 Apr 1;134(7):1741-50.

Tibes R, Mesa RA. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. Journal of hematology & oncology. 2014 Dec;7(1):18.

Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. haematologica. 2014 Feb 1;99(2):292-8.

Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, Tibes R, Mesa R. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Leukemia & lymphoma. 2014 Jan 1;55(1):195-7.

2013

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and therapy. 2013;7:13-21.

Gowin K, Emanuel R, Geyer H, Mesa RA. The new landscape of therapy for myelofibrosis. Current hematologic malignancy reports. 2013 Dec 1;8(4):325-32.

Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis–an update of its clinical effects. Clinical Lymphoma Myeloma and Leukemia. 2013 Dec 1;13(6):638-45.

Gowin K, Mesa R. Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. Expert opinion on investigational drugs. 2013 Dec 1;22(12):1603-11.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec 1;98(12):1865-71.

Mesa RA. Clearing the path for MPN therapy monitoring. Blood. 2013 Nov 28;122(23):3704-5.

Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. Journal of hematology & oncology. 2013 Dec;6(1):79.

Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert review of hematology. 2013 Oct 1;6(5):511-23.

Abelsson J, Andréasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leukemia & lymphoma. 2013 Oct 1;54(10):2226-30.

Tibes R, Mesa RA. Emerging drugs for polycythemia vera. Expert opinion on emerging drugs. 2013 Sep 1;18(3):393-404.

Mesa RA, Silver RT, Verstovsek S, Mascarenhas J, Kessler CM, Rondelli D, Goldberg JD, Marchioli R, Demakos EP, Silverman LR, Hoffman R. Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. haematologica. 2013 Sep 1;98(9):1421-3.

Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R. Revised response criteria for myelofibrosis: international Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013 Aug 22;122(8):1395-8.

DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS. Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis. British journal of haematology. 2013 Aug;162(3):326-35.

Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leukemia research. 2013 Aug 1;37(8):911-6.

Harrison CN, Mesa RA, Kiladjian JJ, Al‐Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley‐Merriman C. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British journal of haematology. 2013 Jul;162(2):229-39.

Mesa RA. Improving disease burden in myelofibrosis: changing the natural history of the disease. Oncology (Williston Park, NY). 2013 Jul 1;27(7):715-6.

Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 6;121(23):4778-81.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British journal of haematology. 2013 May;161(4):508-16.

Hensley B, Geyer H, Mesa R. Polycythemia vera: current pharmacotherapy and future directions. Expert opinion on pharmacotherapy. 2013 Apr 1;14(5):609-17.

Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology. 2013 Apr 1;31(10):1285.

Cervantes F, Mesa R, Harrison C. JAK inhibitors: beyond spleen and symptoms?. haematologica. 2013 Feb 1;98(2):160-2.

Mesa RA. The evolving treatment paradigm in myelofibrosis. Leukemia & lymphoma. 2013 Feb 1;54(2):242-51.

Keohane C, Mesa R, Harrison C. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms. InAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013 (pp. 301-305).

2012

Tibes R, Bogenberger JM, Mesa RA. JAK inhibition: the key to treating myeloproliferative neoplasm?. Expert review of hematology. 2012 Dec 1;5(6):583-5.

Mesa RA, Tibes R. MPN blast phase: clinical challenge and assessing response. Leukemia research. 2012 Dec;36(12):1496-7.

Tibes R, Bogenberger JM, Geyer HL, Mesa RA. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert opinion on investigational drugs. 2012 Dec 1;21(12):1755-74.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, Te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Fuentes AK. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of clinical oncology. 2012 Nov 20;30(33):4098.

Tibes R, Bogenberger JM, Benson KL, Mesa RA. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. Molecular diagnosis & therapy. 2012 Oct 1;16(5):269-83.

Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. haematologica. 2012 Oct 1;97(10):1570-3.

Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR, Camoriano J, Noel P, Fauble V, Betcher J, Higgins MS. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leukemia research. 2012 Sep 1;36(9):1147-51.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, Green AR, Michaeel NG, Gilleece MH, Hall GW, Knapper S. Guideline for the diagnosis and management of myelofibrosis. British journal of haematology. 2012 Aug;158(4):453-71.

Fauble V, Leis J, Mesa RA. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Leukemia supplements. 2012 May;1(S1):S2.

Harrison C, Verstovsek S, McMullin MF, Mesa R. J anus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. British journal of haematology. 2012 May;157(4):426-37.

Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology. 2012 Apr 1;17(sup1):s129-32.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine. 2012 Mar 1;366(9):799-807.

Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgegård G, Andréasson B. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leukemia & lymphoma. 2012 Mar 1;53(3):441-4.

Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib.

Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A. Long‐term outcome of pomalidomide therapy in myelofibrosis. American journal of hematology. 2012 Jan;87(1):66-8.

2011

Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson‐Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 1;117(21):4869-77.

Gregory SA, Mesa RA, Hoffman R, Shammo JM. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clinical advances in hematology & oncology: H&O. 2011 Sep;9(9 Suppl 22):1-6.

Mesa RA. Transplantation for myelofibrosis: time for a randomized trial. Leukemia research. 2011 Aug;35(8):987.

Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011 Jul 14;118(2):401-8.

Tibes R, Mesa RA. Blood consult: resistant and progressive essential thrombocythemia. Blood. 2011 Jul 14;118(2):240-2.

Tibes R, Mesa RA. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?. Leukemia & lymphoma. 2011 Jul 1;52(7):1178-87.

Van Etten RA, Koschmieder S, Delhommeau F, Perrotti D, Holyoake T, Pardanani A, Mesa R, Green T, Ibrahim AR, Mughal T, Gale RP. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. haematologica. 2011 Apr 1;96(4):590-601.

Scherber R, Mesa RA. Future therapies for the myeloproliferative neoplasms. Current hematologic malignancy reports. 2011 Mar 1;6(1):22-7.

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology. 2011 Feb 20;29(6):761.

Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb;25(2):301.

Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. MPN-associated myelofibrosis (MPN-MF). Leukemia research. 2011 Jan;35(1):12-3.

Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. American journal of hematology. 2011 Jan;86(1):96-8.

2010

Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010 Nov 25;116(22):4436-8.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine. 2010 Sep 16;363(12):1117-27.

Mesa RA. Detangling fibrosis assessment in MPNs. Leukemia research. 2010 Jul 1;34(7):854-5.

Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs: the investigational drugs journal. 2010 Jun;13(6):394-403.

Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms. Blood. 2010 Apr 8;115(14):2882-90.

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British journal of haematology. 2010 Mar;148(6):961-3.

Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, Hogan WJ, Tefferi A. Phase1/‐2 study of Pomalidomide in myelofibrosis. American journal of hematology. 2010 Feb;85(2):129-30.

Mesa RA. New drugs for the treatment of myelofibrosis. Current hematologic malignancy reports. 2010 Jan 1;5(1):15-21.

Mesa RA. Assessing new therapies and their overall impact in myelofibrosis. ASH Education Program Book. 2010 Dec 4;2010(1):115-21.

2009

Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia. 2009 Oct;23(10):1708.

Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of Clinical Oncology. 2009 Sep 20;27(27):4563.

Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert opinion on emerging drugs. 2009 Sep 1;14(3):471-9.

Mesa R, Gale RP. Hypothesis: How do JAK2-inhibitors work in myelofibrosis. Leukemia research. 2009 Sep 1;33(9):1156-7.

Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia research. 2009 Sep 1;33(9):1199-203.

Mesa RA. Itchy mast cells in MPNs. Blood. 2009 Jun 4;113(23):5697-8.

Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood. 2009 May 28;113(22):5394-400.

Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not. American journal of hematology. 2009 May;84(5):265-7.

Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May;23(5):905.

Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. European journal of haematology. 2009 Apr;82(4):255-9.

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009 Mar 26;113(13):2895-901.

Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia. 2009 Jan;23(1):180.

2008

Hussein K, Ketterling RP, Dewald GW, Van Dyke DL, Mesa R, Tefferi A. Peripheral Blood Cytogenetic Studies in Myelofibrosis: Overall Yield and Comparison with Bone Marrow Cytogenetic Studies. Leukemia research. 2008 Oct;32(10):1597-1600

Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia. 2008 Aug;22(8):1636.

Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2008 Jun 15;112(12):2726-32.

Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, Mesa R, McClure RF, Li CY, Hanson CA. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. European journal of haematology. 2008 May;80(5):386-90.

Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leukemia research. 2008 May 1;32(5):691-8.

Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. American journal of hematology. 2008 May;83(5):363-5.

Mesa R. Myeloproliferative disorder-associated massive splenomegaly. Clinical advances in hematology & oncology: H&O. 2008 Apr;6(4).

Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008 Apr;22(4):756.

Kröger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia. 2008 Mar;22(3):474.

Mesa RA. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Current opinion in hematology. 2008 Mar 1;15(2):121-6.

Knoll B, Rea DJ, Szoztek J, Nagorney DS, Tefferi A, Mesa RA. Images submission: Extramedullary hematopoiesis. American journal of hematology. 2008 Feb;83(2):171-.

Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008 Feb;22(2):437.

2007

Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leukemia research. 2007 Nov 1;31(11):1503-9.

Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. The Cancer Journal. 2007 Nov 1;13(6):377-83.

Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007 Sep;25(9):2358-62.

Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007 Sep;21(9):1964.

Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15;110(4):1092-7.

Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del (5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007 Aug;21(8):1827.

Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007 Aug;21(8):1658.

Mesa RA. The dawn of targeted therapy for primary myelofibrosis: Opportunities and challenges. Leukemia research. 2007 Jul 1;31(7):883-6.

Mesa RA. Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics: targets & therapy. 2007 Jun;1(2):129.

Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia research. 2007 Jun 1;31(6):737-40.

Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007 May 15;109(10):2083-8.

Mesa RA, Quintás-Cardama A, Verstovsek S. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Current hematologic malignancy reports. 2007 Feb 1;2(1):25-33.

Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) An international internet‐based survey of 1179 MPD patients. Cancer. 2007 Jan 1;109(1):68-76.

Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. ASH Education Program Book. 2007 Jan 1;2007(1):355-62.

2006

Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gary Gilliland D, Tefferi A. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. British journal of haematology. 2006 Dec;135(5):683-7.

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15;108(10):3472-6.

Mesa RA, Powell H, Lasho T, DeWald G, McClure R, Tefferi A. JAK2V617F and leukemic transformation in myelofibrosis with myeloid metaplasia. Leukemia research. 2006 Nov 1;30(11):1457-60.

Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2 V617F positive, del (5)(q13q33) myelodysplastic syndrome. Leukemia. 2006 Nov;20(11):2063.

Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. 2006 Oct;20(10):1800.

Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 1;108(5):1497-503.

Mesa RA. Practical management of classical myeloproliferative disorder patients: a clinician’s guide.

Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic. Cancer. 2006 Jul 15;107(2):361-70.

Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Estrogen‐based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer. 2006 Jun 1;106(11):2406-11.

Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006 May 1;106(9):1985-9.

Tefferi A, Strand JJ, Lasho TL, Elliott MA, Li CY, Mesa RA, Dewald GW. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2V617F and response to erythropoietin therapy. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006 Apr 15;106(8):1739-43.

Mesa RA, Powell H, Lasho T, DeWald GW, McClure R, Tefferi A. A longitudinal study of the JAK2 (V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points. Haematologica. 2006 Jan 1;91(3):415-6.

Mesa RA. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert review of anticancer therapy. 2006 Mar 1;6(3):313-9.

Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant‐eligible patients with agnogenic myeloid metaplasia: a simple CBC‐based scoring system. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006 Feb 1;106(3):623-30.

Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG. The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006 Feb 1;106(3):631-5.

Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Practice & Research Clinical Haematology. 2006 Sep 1;19(3):495-517.

2005

Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British journal of haematology. 2005 Nov;131(3):320-8.

Mesa R. Pegylated interferon for the treatment of high-risk essential thrombocythemia. Haematologica. 2005 Oct;90(10):1298B-.

Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG. Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemia. British journal of haematology. 2005 Oct;131(2):166-71.

Lasho TL, Mesa R, Gary Gilliland D, Tefferi A. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2V617F in granulocytes. British journal of haematology. 2005 Sep;130(5):797-9.

Mesa RA, Tefferi A. Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. InSeminars in oncology 2005 Aug 1;32(4):403-413.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer cell. 2005 Apr 1;7(4):387-97.

Faoro LN, Tefferi A, Mesa RA. Long‐term analysis of the palliative benefit of 2‐chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. European journal of haematology. 2005 Feb;74(2):117-20.

Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005 Feb 1;105(3):973-7.

Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high‐risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. European journal of haematology. 2005 Jan;74(1):47-53.

Ho CL, Arora B, Hoyer JD, Wellik LE, Mesa RA, Tefferi A. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. European journal of haematology. 2005 Jan;74(1):35-9.

Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. British journal of haematology. 2005 Jan;128(1):42-8.

 

2004

Arora B, Ho CL, Hoyer JD, Mesa RA, Tefferi A. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica. 2004 Jan 1;89(12):1454-8.

Arora B, Mesa R, Tefferi A. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. Leukemia & lymphoma. 2004 Jan 1;45(12):2373-86.

Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Internal medicine. 2004;43(7):540-7.

Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. InMayo Clinic Proceedings 2004 Jul 1 (Vol. 79, No. 7, pp. 883-889). Elsevier.

Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood. 2004 May 1;103(9):3547-8.

2003

Mesa RA, Steensma DP, Hoyer J, Ketterling RP. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. British journal of haematology. 2003 Oct;123(2):366-7.

Steensma DP, Mesa RA, Reeder TL, Tefferi A, Kaufmann SH. Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow. Haematologica. 2003 Sep 1;88(9):1072-4.

Maziarz RT, Mesa RA, Tefferi A. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is “when?”. InMayo Clinic Proceedings 2003 Aug 1 (Vol. 78, No. 8, pp. 941-943). Elsevier.

Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.

Mesa RA. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Current hematology reports. 2003 May;2(3):264-70.

Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003 Apr 1;101(7):2534-41.

2002

Mesa RA. The therapy of myelofibrosis: targeting pathogenesis. International journal of hematology. 2002 Mar 1;76(2):296-304.

Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. International journal of hematology. 2002 Mar 1;76(2):193-203.

Mesa RA, Hanson CA, Li CY, Yoon SY, Rajkumar SV, Schroeder G, Tefferi A. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood. 2002 Jun 1;99(11):4131-7.

Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002 May 15;99(10):3854-6.

Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, Geyer SM, Tefferi A. Thalidomide treatment in myelofibrosis with myeloid metaplasia. British journal of haematology. 2002 May;117(2):288-96.

Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study: Presented at the 43rd annual American Society of Hematology meeting, Orlando, Florida, December 2001. Blood. 2002 Mar 15;99(6):2252-4.

Rajkumar SV, Mesa RA, Tefferi A. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. Journal of hematotherapy & stem cell research. 2002 Feb 1;11(1):33-47.

2001

Mesa RA, Tefferi A. Palliative splenectomy in myelofibrosis with myeloid metaplasia. Leukemia & lymphoma. 2001 Jan 1;42(5):901-11.

Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS, Yoon SY, Li CY, Gray LA, Margolin S, Hook CC. A phase II trial of pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone), a novel anti‐fibrosing agent, in myelofibrosis with myeloid metaplasia. British journal of haematology. 2001 Jul;114(1):111-3.

Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood. 2001 Jun 1;97(11):3665-7.

Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. British journal of haematology. 2001 Jun;113(3):763-71.

Tefferi A, Elliott MA, Yoon SY, Li CY, Mesa RA, Call TG, Dispenzieri A. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood. 2001 Mar 15;97(6):1896-7.

Tefferi A, Jiménez T, Gray LA, Mesa RA, Chen MG. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. European journal of haematology. 2001 Jan;66(1):37-42.

2000

Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000 Nov 15;96(10):3374-80.

Mesa RA, Elliott MA, Tefferi A. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. Blood reviews. 2000 Sep 1;14(3):121-9.

Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000 Apr 1;95(7):2226-33.

1999

Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. British journal of haematology. 1999 Sep;106(3):682-8.

Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. American journal of hematology. 1999 May;61(1):10-5.

1997

Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. InSeminars in thrombosis and hemostasis 1997 Aug;23(4):379-383. Copyright© 1997 by Thieme Medical Publishers, Inc..